Sustained Benefit of Blinatumomab in Infants With KMT2A-Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics Among N = 300 patients, 74.7% was female, 76.5% was White, and 19.0% was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results